• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Genprex Inc.

    1/24/25 4:52:45 PM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GNPX alert in real time by email
    S-8 1 gnpx20241205_s8.htm FORM S-8 gnpx20241205_s8.htm

     

    As filed with the Securities and Exchange Commission on January 24, 2025

    Registration No. 333-

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT UNDER

    THE SECURITIES ACT OF 1933

     

    GENPREX, INC.

    (Exact name of registrant as specified in its charter)

     

       

    Delaware

     

    90-0772347

     

     

       

    (State or other jurisdiction of
    incorporation or organization)

     

    (I.R.S. Employer
    Identification Number)

     

     

     

     

     

     

    3300 Bee Cave Road #650-227

    Austin, Texas

      78746

     

     
     

     

    (Address of Principal Executive Offices)

      (Zip Code)

     

     

     

     

     

    Genprex, Inc. 2018 Equity Incentive Plan

     

     
     

     

    (Full title of the plan)

     

     

     

     

     

    Ryan M. Confer

    President, Chief Executive Officer, and Chief Financial Officer

    3300 Bee Cave Road #650-227

    Austin, TX 78746

     

     
     

     

    (Name and address of agent for service)

     

     

     

     

     

    (877) 774-4679

     

     
     

     

    (Telephone number, including area code, of agent for service)

     

     

     

    Copies to:

     

    Kate Basmagian, Esq.

    Lowenstein Sandler LLP

    1251 Avenue of the Americas

    New York, New York 10020

    Tel: (212) 262-6700

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

    ☐

     

    Accelerated filer

    ☐

    Non-accelerated filer

    ☒

     

    Smaller reporting company

    ☒

     

     

     

    Emerging growth company

    ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

    EXPLANATORY NOTE

     

    Pursuant to General Instruction E of Form S-8, Genprex, Inc. (the “Registrant”) is filing this Registration Statement on Form S-8 (this “Registration Statement”) with the Securities and Exchange Commission (the “Commission”) for the purpose of registering additional shares of the Registrant’s common stock, par value $0.001 per share (the “Common Stock”), which consists of 543,032 additional shares of Common Stock issuable under the Registrant’s 2018 Equity Incentive Plan (the “2018 Plan”). The number of shares of Common Stock available for grant and issuance under the 2018 Plan is subject to an automatic annual increase on the first day of each fiscal year beginning in 2019 by an amount equal to the lesser of (i) 5% of the outstanding shares of Common Stock on such date or (ii) an amount determined by the Board of Directors (the “Evergreen Provision”). On January 1, 2025, the number of shares of Common Stock available for grant and issuance under the Plan increased by 543,032 shares and this Registration Statement registers such additional shares of Common Stock, which were available for grant and issuance under the Plan pursuant to the Evergreen Provision as of January 1, 2025. 

     

    Pursuant to General Instruction E of Form S-8, the contents of the Registration Statements on Form S-8 of the Registrant filed with the Commission on April 2, 2020 (Registration No. 333-237543), on August 16, 2022 (Registration No. 333-266896), on February 17, 2023 (Registration No. 333-269865) and on April 17, 2024 (Registration No. 333-278758), including any amendments thereto or filings incorporated therein, are incorporated herein by this reference to the extent not replaced or changed hereby.

     

    In accordance with the instructional note to Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of Form S-8 has been omitted from this Registration Statement. 

     

    1

     

     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3.

    Incorporation of Documents by Reference.

     

    The following documents, which have been filed by the Registrant with the Commission pursuant to the Securities Act of 1933, as amended (the “Securities Act”) and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are incorporated herein by reference:

     

     

    ●

    The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Commission on April 1, 2024;

         
      ● The Registrant’s Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2024, June 30, 2024, and September 30, 2024, filed with the Commission on May 15, 2024, August 9, 2024, and November 13, 2024, respectively; 
         
     

    ●

    The Registrant’s Current Reports on Form 8-K filed with the Commission on January 5, 2024, January 31, 2024, February 2, 2024, February 5, 2024, February 26, 2024, March 6, 2024, March 20, 2024, May 9, 2024, June 24, 2024, August 13, 2024, September 4, 2024, September 26, 2024, October 15, 2024, October 24, 2024, November 5, 2024, November 19, 2024, November 20, 2024, December 16, 2024, January 13, 2025, and January 23, 2025 (in each case, other than any portions thereof deemed furnished and not filed); 

         
      ● The Registrant’s Definitive Proxy Statement on Schedule 14A filed with the Commission on April 29, 2024; and 
         
     

    ●

    The description of the Registrant’s Common Stock contained in its Registration Statement on Form 8-A (Registration No. 001-38244) filed with the Commission on October 13, 2017 pursuant to Section 12(b) of the Exchange Act, including any amendments or reports filed for the purpose of updating such description, including Exhibit 4.20 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the Commission on April 1, 2024.

     

    All documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 and 15(d) of the Exchange Act subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment, which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing such documents, except as to specific sections of such documents as set forth therein; provided, however, that documents or information deemed to have been furnished and not filed in accordance with Commission rules shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document, which also is deemed to be incorporated by reference herein, modifies or supersedes such statement.

     

    II-1

     

     

    Item 8.

    Exhibits

     

    Exhibit

    Number

     

    Description of Exhibit

         

    4.1

     

    Amended and Restated Certificate of Incorporation of the Registrant, dated April 3, 2018, as amended by the Certificate of Amendment of the Amended and Restated Certificate of Incorporation, filed with the Secretary of State of the State of Delaware on January 31, 2024 (incorporated by reference to Exhibit 3.1 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the Commission on April 1, 2024).

     

     

     

    4.2

     

    Amended and Restated Bylaws of the Registrant, as amended by Amendment No. 1 adopted and approved by the Registrant’s Board of Directors on October 18, 2023 (incorporated by reference to Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2023 filed with the Commission on November 14, 2023).
         
    4.3   Form of Common Stock Certificate of the Registrant (incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1 (File No. 333-219386), as amended, originally filed on July 21, 2017).

     

     

     

    5.1*

     

    Opinion of Lowenstein Sandler LLP.

     

     

     

    23.1*   Consent of WithumSmith+Brown, PC, Independent Registered Public Accounting Firm.
         
    23.2*   Consent of Daszkal Bolton LLP, Independent Registered Public Accounting Firm.
         

    23.3*

     

    Consent of Lowenstein Sandler LLP (included in Exhibit 5.1).

         

    24.1*

     

    Power of Attorney (included on the signature page to this Registration Statement on Form S-8).
         
    99.1   Genprex, Inc. 2018 Equity Incentive Plan, dated April 3, 2018, including Forms of Award Agreements thereunder (incorporated by reference to Exhibit 10.3 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the Commission on April 1, 2024.
         
    107*   Filing Fee Table.

     

    * Filed herewith.

     

     

    II-2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Austin, State of Texas, on January 24, 2025.

     

     

    GENPREX, INC.

     

     

    By:  /s/ Ryan M. Confer

    Name:  Ryan M. Confer

    Title:    President, Chief Executive Officer and Chief Financial Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Ryan Confer as his true and lawful attorney-in-fact and agent with the full power of substitution, for him in any and all capacities, to sign any and all amendments to this Registration Statement, including any and all post-effective amendments, and to file such amendments thereto, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming that said attorney-in-fact and agent, or his substitute, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

    Title

    Date

     

    /s/ Ryan M. Confer

    Ryan M. Confer

     

    President, Chief Executive Officer, Chief Financial Officer and Director

    (Principal Executive Officer and Principal Financial and Accounting Officer)

     

    January 24, 2025

     

     

     

    /s/ Brent M. Longnecker

    Brent M. Longnecker

    Director

    January 24, 2025
         

    /s/ Jose Antonio Moreno Toscano

    Jose Antonio Moreno Toscano

    Chairman of the Board January 24, 2025
         

    /s/ Will R. Wilson, Jr.

    Will R. Wilson, Jr.

    Director January 24, 2025

     

     

    II-3
    Get the next $GNPX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GNPX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GNPX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Moreno Toscano Jose Antonio was granted 9,000 shares, increasing direct ownership by 5,732% to 9,157 units (SEC Form 4)

    4 - Genprex, Inc. (0001595248) (Issuer)

    12/23/25 5:35:59 PM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Berger Mark Stanley was granted 28,500 shares, increasing direct ownership by 7,917% to 28,860 units (SEC Form 4)

    4 - Genprex, Inc. (0001595248) (Issuer)

    12/23/25 5:35:14 PM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President, CEO and CFO Confer Ryan M. was granted 45,000 shares, increasing direct ownership by 6,808% to 45,661 units (SEC Form 4)

    4 - Genprex, Inc. (0001595248) (Issuer)

    12/23/25 5:34:21 PM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNPX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Genprex Provides Clinical Update on Diabetes Gene Therapy Program

    Company Achieves Clinical Development Milestones in 2025, Advances Program for Future Scale Up and Studies AUSTIN, Texas, Jan. 7, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced a clinical program update on its diabetes gene therapy program for GPX-002, the Company's diabetes gene therapy drug candidate, detailing recent achievements and future advancements. This update follows the recent announcement of positive preliminary preclinical data from studies of GPX-002 in both mouse and non-human primate (NHP) models, specifica

    1/7/26 7:00:00 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies

    Preliminary Preclinical Data Demonstrates In Vivo Proof-of-Concept for Novel Diabetes Gene Therapy in Type 2 Diabetic Non-Human Primates GPX-002 Rejuvenated Exhausted Beta Cells and Normalized Glucose Levels in Type 2 Diabetic Mice AUSTIN, Texas, Jan. 6, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced preliminary in vivo preclinical proof-of-concept data for GPX-002, the Company's diabetes gene therapy drug candidate which may have the potential for long-term control of Type 1 diabetes (T1D) and Type 2 diabetes (T2D), in a

    1/6/26 7:00:00 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer

    Phase 1 Study in Non-Small Cell Lung Cancer Combined Reqorsa® Gene Therapy with Tagrisso® AUSTIN, Texas, Nov. 24, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the publication of data from its Acclaim-1 Phase 1 clinical trial of Reqorsa® Gene Therapy (quaratusugene ozeplasmid) in combination with Tagrisso® (osimertinib) in patients with advanced non-small cell lung cancer (NSCLC) in the peer-reviewed journal Clinical Lung Cancer.

    11/24/25 7:00:00 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNPX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $GNPX
    SEC Filings

    View All

    National Securities initiated coverage on Genprex with a new price target

    National Securities initiated coverage of Genprex with a rating of Buy and set a new price target of $7.00

    1/26/21 7:48:53 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Genprex, Inc. (0001595248) (Filer)

    1/9/26 4:58:44 PM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Genprex Inc.

    S-8 - Genprex, Inc. (0001595248) (Filer)

    1/9/26 4:56:14 PM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genprex Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Genprex, Inc. (0001595248) (Filer)

    1/7/26 7:04:34 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNPX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Genprex Inc.

    SC 13G/A - Genprex, Inc. (0001595248) (Subject)

    10/24/24 12:23:37 PM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Genprex Inc.

    SC 13G - Genprex, Inc. (0001595248) (Subject)

    10/22/24 12:01:59 PM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Genprex Inc.

    SC 13G - Genprex, Inc. (0001595248) (Subject)

    10/3/24 10:09:50 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNPX
    Leadership Updates

    Live Leadership Updates

    View All

    Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors

    Follows the Recent Appointment of Ryan Confer as Genprex President and CEO and to its Board of Directors AUSTIN, Texas, May 13, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Board of Directors has appointed Jose A. Moreno Toscano as non-executive Chairman of the Board following the sudden passing of the Company's co-founder and previous Chairman Rodney Varner. Prior to his appointment as Chairman,

    5/13/24 8:31:00 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairs

    Strengthens management team with seasoned regulatory expert to support pipeline of gene therapies for the treatment of cancer and diabetes, including two clinical trials in Non-Small Cell Lung Cancer and one in Small Cell Lung Cancer AUSTIN, Texas, Aug. 22, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the appointment of Suzanne Thornton-Jones, Ph.D. as Senior Vice President, Regulatory Affairs. Dr. Thornton-Jones will leverage her regulatory expertise to guide and oversee the Company's regulatory submissions and strategy

    8/22/23 7:30:00 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care